M acrolide resistance in Streptococcus pyogenes results primarily from modifi cation of the drug target site by methyltransferases encoded by erm genes, erm(A) and erm(B) or by active effl ux mediated by a mef-encoded effl ux pump. Of these, erm(A) is inducibly expressed (1) and generally confers low-level resistance to macrolides, whereas lincosamides and streptogramins B (MLS B ), which share overlapping binding sites, remain active against erm(A)-harboring S. pyogenes (2) . Conversely, erm(B) can be constitutively or inducibly expressed and confers highlevel resistance to MLS B (2) . mef(A) also is constitutively expressed but confers low to moderate resistance to 14-and 15-membered macrolides and susceptibility to 16-membered MLS B (2) .
That macrolide use is the main driver of macrolide resistance in streptococci has been well demonstrated at the population and individual levels (3, 4) . Because erm and mef are cocarried with tet genes on mobile elements, tetracycline use also affects macrolide resistance (4). In addition, acquisition of resistance often confers a cost to bacteria, the magnitude of which is the main parameter infl uencing the rate of development and stability of the resistance mechanisms and, conversely, the rate at which resistance would decrease under decreasing use of antimicrobial drugs (5) . We investigated temporal changes in the molecular epidemiology of macrolide-resistant S. pyogenes during 1999-2009 in relation to strain fi tness (i.e., ability of bacteria to survive and reproduce) and to outpatient use of MLS B and tetracycline in Belgium.
The Study
We screened 11,819 S. pyogenes isolates from patients with tonsillopharyngitis or invasive disease in Belgium during 1999−2009 for macrolide resistance. We used double-disk diffusion, MIC testing, and multiplex PCR to detect erm and mef genes and investigated their clonality by emm typing and by pulsed-fi eld gel electrophoresis (6) Notwithstanding clonal changes, the fi tness costs (i.e., an organism's decreased ability to survive and reproduce because of a genetic change, expressed as a decreased bacterial growth rate) associated with particular resistance mechanisms is another major factor governing the relation between use and resistance. Mathematical models have shown threshold levels of antimicrobial drug use below which the frequency of resistance would not increase if resistance imposes a fi tness cost for the bacteria (11) . We further hypothesized that the frequency of certain macrolide-resistant geno-emm-types might differ if antimicrobial drug use remains below a certain threshold. In concordance with the models, we found a negative correlation between use of MLS B and tetracycline and proportions of erm(A)-emm77 among macrolideresistant S. pyogenes (p = 0.0002), and we identifi ed 0.62 packages/1,000 inhabitants/day as the critical threshold volume of MLS B and tetracycline use below which proportions of erm(A)-emm77 among macrolide-resistant S. pyogenes would increase signifi cantly (p<0.0001). Next, we compared the fi tness of erm(A)-emm77 with that of 6 other major macrolide-resistant geno-emmtypes in Belgium during 1999-2009 (Figure 2 ). After growth-competition experiments (12), initial and fi nal proportions of competing strains were determined by multiplex PCR to detect erm(B), erm(A), or mef(A) in 50 randomly selected colonies per plated mixture. Number of generations and relative fi tness of competed pairwise strains were calculated as described (13) . The inducible erm(A) in an emm77 background was more fi t (67%) than most of the geno-emm-types that predominated during the previous years of higher MLS B and tetracycline use (Table) .
Only the mef(A)-emm1 and erm(B)-emm28
geno-emm-types were equally as fi t as erm(A)-emm77. Foucault et al. (14) showed that in the noninduced state, the inducible vanB gene had no effect on fi tness of enterococci and might explain the low fi tness cost of erm(A) carriage in emm77 strains. A predominance of erm(A)-harboring strains during 1993-2002, with 30% in an emm77 background, was also reported in Norway, a country with a low prevalence of resistance (2.7%) and antimicrobial drug use (15) . Of note here is the combination of erm(A) and emm77 as geno-emm-type because the fi tness benefi t (i.e., lack of fi tness cost) was not as remarkable for other erm(A)-harboring emm types (data not shown). The mechanisms underlying the higher fi tness benefi t conferred by an emm77 versus another emm background for the erm(A) genetic element remain to be investigated and might be related to differences in basal gene expression or compensatory changes in the emm77 genome or might result from differences in the genetic element harboring erm(A) in emm77.
Conclusions
Using macrolide-resistant S. pyogenes as a marker for use of MLS B and tetracycline, we showed a decrease in use of these antimicrobial drugs, accentuated by successful public health campaigns, refl ected a steady decline of macrolide-resistant S. pyogenes in Belgium. Furthermore, successfully maintaining use below a critical threshold resulted in maintenance of low-level macrolideresistant S. pyogenes and emergence of the inducibly expressed and low-level resistant erm(A)-emm77 genoemm-type. Maintaining antimicrobial drug use below a critical threshold might facilitate stabilization of low-level antimicrobial drug resistance and of milder resistance mechanisms with lower fi tness costs. This study was partly funded by the Belgian Antibiotic Policy Coordination Committee.
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